Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy

Keyphrases

• Clinical Trials 100%
• Postmarketing 100%
• Postmarketing Safety 100%
• Onasemnogene Abeparvovec 100%
• Clinical Trial Safety 100%
• Nonhuman Primate 75%
• Dorsal Root Ganglion 50%
• Prednisolone 50%
• Thrombotic Microangiopathy 50%
• Hepatotoxicity 50%
• Liver 25%
• Neonatal Mice 25%
• Adverse Events 25%
• Inflammation 25%
• Clinical Data 25%
• Platelet Count 25%
• Clinical Examination 25%
• Spinal muscular Atrophy 25%
• Potential Risk 25%
• Safety Data 25%
• Thrombocytopenia 25%
• Treatment-related Adverse Events 25%
• Target Organ 25%
• Adverse Event Reporting 25%
• Medication Use 25%
• Toxicity Study 25%
• Medical Intervention 25%
• Sensory Neuropathy 25%
• Treatment-related 25%
• Bleeding Complications 25%
• Laboratory Evaluation 25%
• Concomitant Medications 25%
• Cardiac Evaluation 25%
• Post-marketing Surveillance 25%
• Intracardiac Thrombus 25%
• Gene Replacement Therapy 25%
• Adverse Event Monitoring 25%
• Monitoring Vital Signs 25%
• Cynomolgus 25%
• Single-dose Toxicity 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Trial 100%
• Onasemnogene Abeparvovec 100%
• Adverse Event 66%
• Preclinical Study 33%
• Prednisolone 33%
• Thrombotic Thrombocytopenic Purpura 33%
• Hepatotoxicity 33%
• Clinical Study 16%
• Inflammation 16%
• Bleeding 16%
• Replacement Therapy 16%
• Thrombocytopenia 16%
• Thrombus 16%
• Sensory Neuropathy 16%
• Spinal Muscular Atrophy 16%
• Postmarketing Surveillance 16%
• Single Dose Toxicity Study 16%